All In Biotech

Drug Trial Radar · NCT02727803

Personalized NK Cell Therapy in CBT

Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

May 19, 2016

Primary completion

May 31, 2027

Study completion May 31, 2027

Sponsor

Lead sponsor
M.D. Anderson Cancer CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI)
First posted
Apr 5, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 15 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II clinical trial studies how well personalized natural killer (NK) cell therapy works after chemotherapy and umbilical cord blood transplant in treating patients with myelodysplastic syndrome, leukemia, lymphoma or multiple myeloma. This clinical trial will test cord blood (CB) selection for human leukocyte antigen (HLA)-C1/x recipients based on HLA-killer-cell immunoglobulin-like receptor (KIR) typing, and adoptive therapy with CB-derived NK cells for HLA-C2/C2 patients. Natural killer cells may kill tumor cells that remain in the body after chemotherapy treatment and lessen the risk of graft versus host disease after cord blood transplant.

Conditions

  • Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • Acute Biphenotypic Leukemia
  • Acute Lymphoblastic Leukemia
  • Acute Lymphoblastic Leukemia in Remission
  • Acute Myeloid Leukemia With Myelodysplasia-Related Changes
  • Acute Myeloid Leukemia With Variant MLL Translocations
  • B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
  • Chemotherapy-Related Leukemia
  • Chronic Myelomonocytic Leukemia
  • Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
  • ISS Stage II Plasma Cell Myeloma
  • ISS Stage III Plasma Cell Myeloma
  • Myelodysplastic Syndrome
  • Myelodysplastic Syndrome With Excess Blasts
  • Myelodysplastic Syndrome With Gene Mutation
  • Myelodysplastic/Myeloproliferative Neoplasm
  • Previously Treated Myelodysplastic Syndrome
  • Recurrent Acute Myeloid Leukemia
  • Recurrent Adult Acute Myeloid Leukemia
  • Recurrent Hodgkin Lymphoma
  • Recurrent Non-Hodgkin Lymphoma
  • Refractory Acute Lymphoblastic Leukemia
  • Refractory Adult Acute Lymphoblastic Leukemia
  • Secondary Acute Myeloid Leukemia
  • Therapy-Related Myelodysplastic Syndrome

Interventions

  • Allogeneic Natural Killer Cell Line NK-92Biological

    Given IV

  • Anti-Thymocyte GlobulinBiological

    Given IV

  • BusulfanDrug

    Given IV

  • ClofarabineDrug

    Given IV

  • CyclophosphamideDrug

    Given IV

  • Fludarabine PhosphateDrug

    Given IV

  • Laboratory Biomarker AnalysisOther

    Correlative studies

  • MelphalanDrug

    Given IV

  • RituximabBiological

    Given IV

  • Total-Body IrradiationRadiation

    Undergo total body irradiation

  • Umbilical Cord Blood TransplantationProcedure

    Undergo umbilical cord blood transplantation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression free survival (PFS) time in C2C2 patientsTime frame: From the date of engraftment to disease progression or death, assessed up to 4 years
  2. Progression free survival (PFS) time in C1 patientsTime frame: From the date of cord blood transplant to disease progression or death, assessed up to 4 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • M D Anderson Cancer Center

    Houston, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.